All sponsors

Pierre Fabre Medicament

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO33%

Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Pierre Fabre Medicament on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
OCEANII
NCT05195632
P2Active, not recruitingNon-Small Cell Lung Cancer632024-05-27 (-6 mo)
COLUMBUS-AD
NCT05270044
P3Active, not recruitingMelanoma8152027-03-31
Tabelecleucel
NCT04554914
P2Active, not recruitingEpstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)1902027-06
STX-241 FIH
NCT06567015
P1/2RecruitingNon-small Cell Lung Cancer (NSCLC)1712027-11-20
STX-721/PFL-721 (Escalated)
NCT06043817
P1/2RecruitingNon-Small Cell Lung Cancer; NSCLC3452029-12-01 (+41 mo)
ALLELE
NCT03394365
P3RecruitingEpstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications1152030-05-31 (+115 mo)
VERT-002
NCT06669117
P1/2RecruitingSolid Tumor; MET Alteration1402030-10-21